AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7614520 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 168
Study 2146369 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid treatment
Number of subjects: 0
Study 2146369 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 361026 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzydamine hydrochloride
Number of subjects: 0
Study 361026 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 31676650 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA)
Number of subjects: 8324
Study 31676650 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary Behaviour (SB)
Number of subjects: 8324
Study 31676650 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive tasks and accelerometers
Number of subjects: 8324
Study 31676650 — intervention group
Group type: EXPERIMENTAL
Intervention: Event-related potentials using electroencephalogram
Number of subjects: 8324
Study 28332191 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Er:YAG (160 mJ/pulse, 10 Hz) and Nd:YAG laser (100 mJ/pulse, 20 Hz) therapy
Number of subjects: 25
Study 28332191 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing alone
Number of subjects: 25
Study 24990956 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery Management Intervention (RMI)
Number of subjects: 100
Study 24142853 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 109
Study 24142853 — intervention group
Group type: COMPARATOR
Intervention: Carperitide
Number of subjects: 109
Study 21444654 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted gait training (20 sessions in the first 4 weeks of inpatient therapy)
Number of subjects: 48
Study 21444654 — intervention group
Group type: COMPARATOR
Intervention: Conventional gait training
Number of subjects: 48
Study 18319446 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 139
Study 18319446 — intervention group
Group type: COMPARATOR
Intervention: Newsletter (Control)
Number of subjects: 139
Study 18319446 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable (Contemplation stage at baseline)
Number of subjects: 139
Study 18319446 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable (Participation barriers)
Number of subjects: 139
Study 17542202 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride toothpaste (Elmex sensitive toothpaste, 1400 ppm F) plus fluoride mouthrinse (Elmex sensitive rinse containing 250 ppm F) used twice a day.
Number of subjects: 100
Study 17542202 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthrinse without fluoride used twice a day with the same fluoride toothpaste.
Number of subjects: 100
Study 17542202 — intervention group
Group type: COMPARATOR
Intervention: Fluoride toothpaste and mouthrinse (Group A) vs. placebo mouthrinse (Group B).
Number of subjects: 100
Study 15509203 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg sublingual sildenafil
Number of subjects: 40
Study 15509203 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 11827307 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin prick tests (SPT)
Number of subjects: 64
Study 11827307 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme-linked immunosorbent assays (ELISA)
Number of subjects: 64
Study 11827307 — intervention group
Group type: COMPARATOR
Intervention: ELISA
Number of subjects: 64
Study 11827307 — intervention group
Group type: COMPARATOR
Intervention: IgE determination
Number of subjects: 64
Study 11827307 — intervention group
Group type: COMPARATOR
Intervention: ELISA alone or in combination with SPT
Number of subjects: 64
Study 9606248 — intervention group
Group type: EXPERIMENTAL
Intervention: Single telephone call reminder 1 day before the appointment
Number of subjects: 703
Study 9606248 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful telephone call reminder
Number of subjects: 703
Study 9606248 — intervention group
Group type: COMPARATOR
Intervention: Control group (no reminder)
Number of subjects: 703
Study 9290020 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex hormone receptors
Number of subjects: 240
Study 1764956 — intervention group
Group type: EXPERIMENTAL
Intervention: Fendiline (75 mg twice daily)
Number of subjects: 79
Study 1764956 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (90 mg twice daily)
Number of subjects: 79
Study 1764956 — intervention group
Group type: COMPARATOR
Intervention: Both medications
Number of subjects: 79
Study 1764956 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 79
Study 1764956 — intervention group
Group type: EXPERIMENTAL
Intervention: Fendiline
Number of subjects: 79
Study 6805031 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (0.75 g/kg) + Naloxone (0.4 mg)
Number of subjects: 39
Study 6805031 — intervention group
Group type: COMPARATOR
Intervention: Ethanol (0.75 g/kg) + Saline
Number of subjects: 39
Study 30943275 — intervention group
Group type: EXPERIMENTAL
Intervention: Azilsartan (20 mg/day)
Number of subjects: 33
Study 30943275 — intervention group
Group type: COMPARATOR
Intervention: Telmisartan (40 mg/day)
Number of subjects: 33
Study 30943275 — intervention group
Group type: EXPERIMENTAL
Intervention: Both azilsartan and telmisartan
Number of subjects: 33
Study 28412954 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality Improvement Campaign (Project JOINTS)
Number of subjects: 188
Study 28412954 — intervention group
Group type: COMPARATOR
Intervention: Non-campaign states
Number of subjects: 188
Study 26453668 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare Assistant (HCA)
Number of subjects: 602
Study 26453668 — intervention group
Group type: COMPARATOR
Intervention: Nurse
Number of subjects: 602
Study 23942133 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral clonidine
Number of subjects: 120
Study 23942133 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral etoricoxib
Number of subjects: 120
Study 23942133 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral gabapentin
Number of subjects: 120
Study 22438298 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month exercise training program (T; n = 15)
Number of subjects: 24
Study 22438298 — intervention group
Group type: COMPARATOR
Intervention: Nontrained group (NT; n = 13)
Number of subjects: 24
Study 22438298 — intervention group
Group type: COMPARATOR
Intervention: Control group (C; n = 8)
Number of subjects: 24
Study 20844421 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent muscle retraction
Number of subjects: 40
Study 20844421 — intervention group
Group type: COMPARATOR
Intervention: Continuous muscle retraction
Number of subjects: 40
Study 18828199 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive intervention and exercises
Number of subjects: 0
Study 18828199 — intervention group
Group type: COMPARATOR
Intervention: Lumbar fusion and postoperative rehabilitation
Number of subjects: 0
Study 15806059 — intervention group
Group type: EXPERIMENTAL
Intervention: Multilevel temperature-controlled radiofrequency tissue ablation (TCRFTA)
Number of subjects: 29
Study 12773446 — intervention group
Group type: EXPERIMENTAL
Intervention: Follitropin beta administered by a pen device
Number of subjects: 200
Study 12773446 — intervention group
Group type: COMPARATOR
Intervention: Follitropin alpha administered by a conventional syringe
Number of subjects: 200
Study 10556614 — intervention group
Group type: EXPERIMENTAL
Intervention: Unexpected words from the expected semantic category presented to the right visual field (left hemisphere)
Number of subjects: 0
Study 10556614 — intervention group
Group type: EXPERIMENTAL
Intervention: Unexpected endings presented to both visual fields
Number of subjects: 0
Study 10556614 — intervention group
Group type: EXPERIMENTAL
Intervention: Unexpected endings presented to the left visual field (right hemisphere)
Number of subjects: 0
Study 10556614 — intervention group
Group type: EXPERIMENTAL
Intervention: Context processing in the right hemisphere
Number of subjects: 0
Study 10556614 — intervention group
Group type: EXPERIMENTAL
Intervention: Context processing in the left hemisphere
Number of subjects: 0
Study 9170039 — intervention group
Group type: EXPERIMENTAL
Intervention: 3He MRI imaging in healthy volunteers
Number of subjects: 18
Study 9170039 — intervention group
Group type: EXPERIMENTAL
Intervention: 3He MRI imaging in patients with chronic obstructive lung disease or bronchiectasis
Number of subjects: 18
Study 9170039 — intervention group
Group type: EXPERIMENTAL
Intervention: 3He MRI imaging in patients with bronchogenic carcinoma, chronic empyema, lymphadenopathy, or pleural effusion
Number of subjects: 18
Study 9170039 — intervention group
Group type: EXPERIMENTAL
Intervention: 3He MRI
Number of subjects: 18
Study 1492932 — intervention group
Group type: EXPERIMENTAL
Intervention: Eflornithine (400 mg/kg daily, continuous intravenous infusion)
Number of subjects: 98
Study 1492932 — intervention group
Group type: COMPARATOR
Intervention: Cotrimoxazole (3.84 g twice daily, intravenously)
Number of subjects: 98
Study 1492932 — intervention group
Group type: EXPERIMENTAL
Intervention: Eflornithine (400 mg/kg daily)
Number of subjects: 98
Study 1492932 — intervention group
Group type: COMPARATOR
Intervention: Cotrimoxazole (7.68 g daily)
Number of subjects: 98
Study 3887955 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-gut lavage
Number of subjects: 121
Study 3887955 — intervention group
Group type: COMPARATOR
Intervention: Enemas and purgatives
Number of subjects: 121
Study 3887955 — intervention group
Group type: EXPERIMENTAL
Intervention: Colostomy closure
Number of subjects: 121
Study 3887955 — intervention group
Group type: EXPERIMENTAL
Intervention: Remaining procedures excluding colostomy closure
Number of subjects: 121
Study 3887955 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall complications
Number of subjects: 121
Study 30529930 — intervention group
Group type: EXPERIMENTAL
Intervention: CT angiography
Number of subjects: 9486
Study 30529930 — intervention group
Group type: COMPARATOR
Intervention: Stress testing
Number of subjects: 9486
Study 30529930 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheterization
Number of subjects: 9486
Study 30529930 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin use
Number of subjects: 9486
Study 30529930 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin use
Number of subjects: 9486
Study 30529930 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall outcomes
Number of subjects: 9486
Study 30203749 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat
Number of subjects: 160
Study 30203749 — intervention group
Group type: COMPARATOR
Intervention: Allopurinol (Control)
Number of subjects: 160
Study 26936480 — intervention group
Group type: EXPERIMENTAL
Intervention: Youth mentor-led nutritional intervention (BHCK); bi-weekly interactive sessions delivered by 16 youth leaders.
Number of subjects: 0
Study 25074318 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 66
Study 25074318 — intervention group
Group type: COMPARATOR
Intervention: Voglibose
Number of subjects: 66
Study 22392001 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive lifestyle modification program
Number of subjects: 1300
Study 22392001 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaging technology (positron emission tomography) for risk stratification
Number of subjects: 1300
Study 19249751 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal cocaine self-administration (1.0 mg/kg)
Number of subjects: 10
Study 19249751 — intervention group
Group type: COMPARATOR
Intervention: Placebo powder
Number of subjects: 10
Study 17878772 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-session structured group format memory rehabilitation program
Number of subjects: 12
Study 17878772 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 12
Study 15354898 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-imaging simulation
Number of subjects: 24
Study 15354898 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-based composite/esthetic preview/mock-up
Number of subjects: 24
Study 15354898 — intervention group
Group type: EXPERIMENTAL
Intervention: Photographs of other patients
Number of subjects: 24
Study 15354898 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic models with wax setups
Number of subjects: 24
Study 11684981 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 45
Study 11684981 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 45
Study 11684981 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 45
Study 8098220 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of bisoprolol daily for two weeks
Number of subjects: 6
Study 8098220 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 3101553 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate eye ointment
Number of subjects: 31
Study 3101553 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 31568587 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose exercise (150 minutes per week)
Number of subjects: 116
Study 31568587 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose exercise (300 minutes per week)
Number of subjects: 116
Study 31568587 — intervention group
Group type: COMPARATOR
Intervention: Control (<75 minutes per week)
Number of subjects: 116
Study 29277462 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent education through home visits by trained community health workers
Number of subjects: 100
Study 29277462 — intervention group
Group type: COMPARATOR
Intervention: Control group (no home visits)
Number of subjects: 100
Study 29277462 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula feeding
Number of subjects: 100
Study 29277462 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding for ≥2 months
Number of subjects: 100
Study 29277462 — intervention group
Group type: EXPERIMENTAL
Intervention: Father living with mother at prenatal visit
Number of subjects: 100
Study 28551073 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab every 4 weeks (80 mg after a 160 mg starting dose)
Number of subjects: 363
Study 28551073 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab every 2 weeks (80 mg after a 160 mg starting dose)
Number of subjects: 363
Study 28551073 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 363
Study 28551073 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab every 4 weeks
Number of subjects: 363
Study 28551073 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab every 2 weeks
Number of subjects: 363
Study 26228487 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 236
Study 26228487 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 236
Study 22846777 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 22846777 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg liraglutide
Number of subjects: 10
Study 22846777 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 mg liraglutide
Number of subjects: 10
Study 22846777 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 mg liraglutide
Number of subjects: 10
Study 21905751 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed nuts consumption (30 g/day)
Number of subjects: 0
Study 21905751 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 0
Study 18652688 — intervention group
Group type: EXPERIMENTAL
Intervention: GK 420
Number of subjects: 16
Study 18652688 — intervention group
Group type: EXPERIMENTAL
Intervention: Remstar Auto
Number of subjects: 16
Study 18652688 — intervention group
Group type: EXPERIMENTAL
Intervention: Autoset Spirit
Number of subjects: 16
Study 18652688 — intervention group
Group type: COMPARATOR
Intervention: Other devices (not specified)
Number of subjects: 16
Study 16492236 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 25 mg
Number of subjects: 783
Study 16492236 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg
Number of subjects: 783
Study 16492236 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 783
Study 16492236 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 783
Study 14633540 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS-guided
Number of subjects: 90
Study 14633540 — intervention group
Group type: EXPERIMENTAL
Intervention: AEP-guided
Number of subjects: 90
Study 14633540 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 90
Study 10673488 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiological guidelines sent to GPs in the intervention group (33 practices) with feedback after 9 months.
Number of subjects: 69
Study 10673488 — intervention group
Group type: COMPARATOR
Intervention: Control practices (36 practices) received the guidelines at the end of the study.
Number of subjects: 69
Study 9393746 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinamide (80 mg/kg)
Number of subjects: 10
Study 9393746 — intervention group
Group type: COMPARATOR
Intervention: Carbogen breathing
Number of subjects: 10
Study 7504854 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.5% oxypolygelatine
Number of subjects: 28
Study 7504854 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch 200/0.5
Number of subjects: 28
Study 7504854 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% dextran 40
Number of subjects: 28
Study 7504854 — intervention group
Group type: COMPARATOR
Intervention: saline solution
Number of subjects: 28
Study 3616496 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime
Number of subjects: 93
Study 3616496 — intervention group
Group type: EXPERIMENTAL
Intervention: Netilmicin
Number of subjects: 93
Study 3616496 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime plus netilmicin
Number of subjects: 93
Study 3616496 — intervention group
Group type: COMPARATOR
Intervention: Control (Cefotaxime)
Number of subjects: 93
Study 29747583 — intervention group
Group type: EXPERIMENTAL
Intervention: WeCareAdvisor (WCA)
Number of subjects: 57
Study 29747583 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 57
Study 28253920 — intervention group
Group type: EXPERIMENTAL
Intervention: Image-guided intensity-modulated radiotherapy (10x3Gy)
Number of subjects: 0
Study 28253920 — intervention group
Group type: COMPARATOR
Intervention: Conventionally fractionated external beam radiotherapy (10x3Gy)
Number of subjects: 0
Study 26142600 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenotonsillectomy (T&A)
Number of subjects: 37
Study 26142600 — intervention group
Group type: COMPARATOR
Intervention: Control group (children with SDB without NE)
Number of subjects: 37
Study 24005608 — intervention group
Group type: EXPERIMENTAL
Intervention: Mekabu fucoidan (MF) 300 mg/d
Number of subjects: 70
Study 24005608 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 21411551 — intervention group
Group type: EXPERIMENTAL
Intervention: LB03002
Number of subjects: 152
Study 20120397 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Number of subjects: 85
Study 20120397 — intervention group
Group type: COMPARATOR
Intervention: Vitamin C
Number of subjects: 85
Study 17418538 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided discontinuation strategy
Number of subjects: 128
Study 17418538 — intervention group
Group type: COMPARATOR
Intervention: Maintenance treatment
Number of subjects: 128
Study 15298073 — intervention group
Group type: EXPERIMENTAL
Intervention: NCX-701 (nitric oxide-releasing derivative of paracetamol)
Number of subjects: 0
Study 11703886 — intervention group
Group type: EXPERIMENTAL
Intervention: Serotonin agents
Number of subjects: 0
Study 8990428 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially home-based moderate-intensity aerobic exercise program (30 minutes, 3-4 times weekly at 70% of estimated maximal heart rate)
Number of subjects: 33
Study 8990428 — intervention group
Group type: COMPARATOR
Intervention: No exercise (control group maintained current activity level)
Number of subjects: 33
Study 8990428 — intervention group
Group type: COMPARATOR
Intervention: No exercise (control group)
Number of subjects: 33
Study 8990428 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially home-based moderate-intensity aerobic exercise program
Number of subjects: 33
Study 8491069 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg ibuprofen
Number of subjects: 39
Study 8491069 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/kg acetaminophen
Number of subjects: 39
Study 8491069 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 8491069 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg ibuprofen and 15 mg/kg acetaminophen
Number of subjects: 39
Study 3574862 — intervention group
Group type: EXPERIMENTAL
Intervention: Etidocaine 1%
Number of subjects: 80
Study 3574862 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine 2% and Bupivacaine 0.75%
Number of subjects: 80
Study 3574862 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study 29180522 — intervention group
Group type: EXPERIMENTAL
Intervention: Glecaprevir and pibrentasvir combination regimen for 8 weeks in DAA-treatment-naive GT1a (n=4), GT1b (n=128), and GT2 (n=97) noncirrhotic patients.
Number of subjects: 332
Study 29180522 — intervention group
Group type: EXPERIMENTAL
Intervention: Glecaprevir and pibrentasvir combination regimen for 12 weeks in DAA-treatment-naive GT1b (n=38) and GT2 (n=20) patients with compensated cirrhosis.
Number of subjects: 332
Study 29180522 — intervention group
Group type: EXPERIMENTAL
Intervention: Glecaprevir and pibrentasvir combination regimen for 12 weeks in DAA-experienced patients (n=33).
Number of subjects: 332
Study 29180522 — intervention group
Group type: EXPERIMENTAL
Intervention: Glecaprevir and pibrentasvir combination regimen for 12 weeks in GT3-infected patients (n=12).
Number of subjects: 332
Study 29180522 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline prevalence of NS3-D168E, NS5A-L31M, and NS5A-Y93H in DAA-naive GT1b-infected patients.
Number of subjects: 332
Study 29180522 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline prevalence of NS3-D168E/T/V and NS5A-L31F/I/M/V in DAA-experienced GT1b-infected patients.
Number of subjects: 332
Study 29180522 — intervention group
Group type: EXPERIMENTAL
Intervention: Impact of common baseline polymorphisms in NS3 and/or NS5A on treatment outcomes.
Number of subjects: 332